A B S T R A C T
Background. Currently, there are few strategies for improving the quality of life (QOL) in patients with autosomal dominant polycystic kidney disease (ADPKD) and massive kidneys. Renal transcatheter arterial embolization (TAE) reduces kidney volume, but its impact on QOL in ADPKD patients on hemodialysis is unknown. This study investigated the influence of renal TAE on QOL in ADPKD patients with massive kidneys receiving hemodialysis. Methods. This prospective observational study enrolled 188 ADPKD patients on hemodialysis (92 men and 96 women; mean age 56.7 6 9.1 years) who underwent renal TAE at Toranomon Hospital between August 2010 and July 2014. The 36-item Short Form Health Survey (SF-36) and our original 15-item questionnaire were used to evaluate QOL. Results. Using a linear mixed model, the least squares mean values of the SF-36 physical component summary (PCS), mental component summary (MCS) and role/social component summary (RCS) before renal TAE were calculated as 38. 21 22-52.12 ; P < 0.001), respectively, 1 year after renal TAE. Scores for abdominal fullness, poor appetite and heartburn showed marked improvement after renal TAE, while scores for fever, bodily pain and sleep disorder also improved slightly, but significantly. Scores for constipation and use of analgesics/sleeping medications/laxatives did not improve significantly. All of the SF-36 scores and the scores for specific symptoms (except bodily pain, snoring and constipation) were significantly correlated with the sequential decrease of the height-adjusted total kidney volume. Conclusions. In ADPKD patients on hemodialysis, renal TAE was effective in improving abdominal fullness, appetite, heartburn and SF-36 scores (MCS and RCS scores), but not for sleep disturbance, constipation and physical strength (PCS score).
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I N T R O D U C T I O N
Autosomal dominant polycystic kidney disease (ADPKD) is a common hereditary disorder that affects approximately 1 in every 400-1000 live births [1, 2] . According to a recent population study using registry data, the estimated point prevalence of ADPKD is $3.96/10 000 persons [3] . Sometimes ADPKD is clinically silent [1] , but the majority of persons with this disease develop massive enlargement of the kidneys and renal dysfunction, leading to a requirement for renal replacement therapy at a mean age of 58 years [4] . Patients with massive kidneys have various symptoms related to abdominal distension and renal dysfunction, which impair their quality of life (QOL) [5, 6] , but there are currently few options for improving the QOL of ADPKD patients. Only kidney transplantation and bilateral nephrectomy have been reported to improve QOL in patients with massive kidneys [7, 8] , but open bilateral nephrectomy has a high mortality rate in such patients [9, 10] . In addition, kidney
transplantation is sometimes impossible for reasons such as the patient's poor general condition or lack of a donor. In particular, very few patients undergo kidney transplantation in Japan because of a severe donor shortage.
According to data reported by the Japanese Society for Dialysis Therapy at the end of 2015, there are 313 217 patients on dialysis in Japan and 3.6% of them have ADPKD, with its prevalence increasing annually. Renal transcatheter arterial embolization (TAE) is sometimes considered as a potential alternative to nephrectomy in ADPKD patients [11, 12] . While abdominal fullness is improved in most patients who undergo TAE [13] , the effect on QOL has not been well documented. From January 1996 through July 2014, we performed renal TAE in 876 symptomatic ADPKD patients on hemodialysis to reduce the volume of massive kidneys [13] [14] [15] . We found large differences in the influence of renal TAE on QOL in these patients, but the reasons for such differences were unclear. Therefore, we performed the present study to clarify the effect of renal TAE on QOL in ADPKD patients on hemodialysis and to identify the characteristics of patients who are indicated for this procedure.
M A T E R I A L S A N D M E T H O D S
This study was reviewed and approved by the ethics committee of Toranomon Hospital (Tokyo and Kawasaki, Japan) in March 2010. Written informed consent was obtained from each participant before enrollment in the study. This study was registered with the University Hospital Medical Information Network (UMIN) as 'Quality of life (QOL) of patients with autosomal dominant polycystic kidney disease (ADPKD): Influence of renal TAE or hepatic TAE on QOL' (UMINID: UMIN000007623, registration number: R000006889). All clinical information was obtained from the medical database of Toranomon Hospital.
P A T I E N T S
A total of 207 symptomatic ADPKD patients on hemodialysis were referred to Toranomon Hospital for renal TAE between August 2010 and July 2014. We enrolled patients in this study according to the inclusion and exclusion criteria in Table 1 . Candidates for renal TAE were on maintenance dialysis and had compression symptoms related to enlarged polycystic kidneys. They all received renal TAE of their own free will and gave written consent after being fully informed about the procedure. We essentially performed renal TAE in all patients referred to us, but we consulted appropriate specialists and carefully assessed each patient's eligibility if they had severe medical complications. Because patients eventually become anuric after renal TAE, it was not usually performed before the urine volume decreased to less than 500 mL/day and the patient had oliguria or anuria. In this study we excluded patients who were <20 years old, patients who received partial renal TAE or unilateral renal TAE and patients who underwent repeat renal TAE. Patients who did not answer the questionnaire survey at any time were also excluded.
Furthermore, patients on continuous ambulatory peritoneal dialysis (CAPD) were excluded because abdominal distention might be influenced by this dialysis method. All enrolled patients met the criteria for diagnosis of ADPKD defined by Pei et al. Table S1 ).
Assessment of QOL
Before undergoing renal TAE, patients were requested to complete two self-administered questionnaires while they were in their usual state. The questionnaires were the 36-item Short Form Health Survey (SF-36) and our 15-item original questionnaire. The SF-36 is one of the most common methods used for evaluating QOL worldwide, including Japan [17] [18] [19] . Mean SF-36 scores obtained in a general Japanese population are available, allowing evaluation of QOL in patients compared with that of the general population. The SF-36 contains 36 questions that evaluate eight dimensions: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning and mental health. The scores for these dimensions are totaled to obtain a physical component summary (PCS) score, a mental component summary (MCS) score and a role/social component summary (RCS) score. We adopted a three-component model because it was reported to be superior to the two-component model and to provide more useful PCS and MCS scores in Japanese subjects [20] . The component summary scores have been validated in studies of various chronic illnesses and can be normalized with reference to the scores obtained in a general Japanese population 50.5 6 15.9 years of age [scores for the general population have a mean value of 50 (SD 10)]. Because pain is common in ADPKD and has a detrimental influence on QOL [21, 22] , the question about pain in the SF-36 ('bodily pain') Patients who were on maintenance dialysis and had compression symptoms related to enlarged polycystic kidneys, including dysphagia, gastroesophageal reflux, early satiety, severe changes of bowel habits, dyspnea and orthopnea that interfered with daily activities. Patients who hoped to receive renal TAE of their own free will and gave written consent after being fully informed about the procedure, including complications such as fever, pain and anuria. Patients who provided answers to the questionnaire survey at least once among all possible time points. Exclusion criteria Patients who were <20 years old. Patients who were on CAPD. Patients who had severe medical complications and were considered to be ineligible for renal TAE by a specialist. Patients receiving partial renal TAE or unilateral renal TAE and patients undergoing repeat renal TAE. Patients who did not agree to participate in this study or did not answer the questionnaire survey at any time point.
was used to assess the relation between pain and the other SF-36 scales.
In addition, we devised an original 15-item questionnaire that assessed specific symptoms of ADPKD patients, such as abdominal distension, poor appetite and sleep disturbance. Each symptom was assigned a score of 1-4 or 1-5, with 1 being the most severe manifestations (Supplementary Table S2 ). The questions were related to common symptoms and medications of ADPKD patients at our hospital and were generated during clinical meetings at our department. The question about snoring was scored from 1 to 5, but a score of 5 corresponded to 'unknown' and therefore was excluded when calculating the least squares mean for snoring. Our questionnaire included a question about regular use of analgesics. In Japan, opiates are not usually prescribed for relief of chronic pain in ADPKD and only two patients received pentazocine. The common analgesics were nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen. Questions about sleeping in the supine position and use of analgesics were added to our questionnaire in February 2011 (6 months after initiation of the study).
Clinical and laboratory assessments
All patients were expected to attend our hospital at 1, 3, 6 and 12 months after renal TAE in order to evaluate the outcome and adjust their dry weight. Clinical findings, including height, body weight and blood pressure (BP), were recorded before performing renal TAE, along with past medical history and smoking history. Body weight and BP were also recorded at 1, 3, 6 and 12 months after renal TAE. Dry weight was used as the body weight. BP was measured in the sitting position with an automatic device and the average of three systolic BP readings measured in the morning on a nondialysis day was used for analysis. Body mass index (BMI) was calculated as the body weight in kilograms divided by the square of the height in meters. Laboratory tests, including the complete blood count and biochemical tests, were done before renal TAE, as well as 1, 3, 6 and 12 months after TAE. Blood samples were obtained at the start of dialysis. All laboratory tests were performed at our hospital by standard automated methods within 24 h of collecting the blood samples.
Imaging studies
Abdominal computed tomography (CT) was routinely performed in all patients before renal TAE with a multiple detector scanner (Aquilion 16, Toshiba), obtaining scans at a slice interval of 1 cm and at 1, 6 and 12 months after TAE.
The volume of each kidney was calculated from CT scans by using the equation for the volume of an ellipsoid: V ¼ a*b*c*p/6, where a is the maximum length of the kidney and b and c are the maximum widths in two transverse dimensions [23] . Total kidney volume (TKV) was then calculated as the sum of the volumes of both kidneys. TKV was determined before renal TAE and at 1, 3, 6 and 12 months after TAE. In addition, each CT scan was analysed using Synapse software (Fujifilm, Tokyo, Japan) to measure the hepatic area (cysts plus parenchyma). The total liver volume (TLV) was then calculated as the sum of all the hepatic areas on the scans. Subsequently, TKV and TLV were adjusted by height to give the height-adjusted TKV (htTKV) and the height-adjusted TLV (htTLV).
Ascites was assessed by two readers (a nephrologist and a radiologist) using our original criteria and was classified according to the amount of fluid surrounding the liver (determined from the minimum distance between the liver surface and abdominal wall): mild, <1 cm, moderate, 1-3 cm; severe, >3 cm.
Renal TAE procedure
The procedure for renal TAE has changed since 1996 [13, 24] , but it has not been altered since January 2006 (including the microcoils used) [13] . After the femoral artery was cannulated, aortography was performed using a pigtail catheter (Beacon, Cook Medical, Bloomington, IN, USA) and selective renal artery angiography was done using a shepherd's hook catheter (Cathex, Tokyo, Japan). A microcatheter (Renegade, Boston Scientific, Marlborough, MA, USA) was inserted into the peripheral branches of the renal artery along a guide wire and platinum microcoils were advanced with a pusher [Trupush, Codman Neuro, Johnson & Johnson, New Brunswick, NJ, USA)]. We utilized two kinds of platinum microcoils: the C-Stopper 18 cm (Piolax Medical Devices, Yokohama, Japan) and the Tornado 14.2 cm (Cook Medical), with the C-Stopper coil generally being employed to obstruct peripheral branches and the Tornado being used for the proximal renal artery. To avoid recanalization, coils were inserted as peripherally as possible into the small renal artery branches and both peripheral and proximal occlusion were performed as completely as possible on both sides simultaneously. When performing TAE, it is desirable to embolize as many branches of the vessels supplying both kidneys as is feasible (including additional renal arteries and capsular arteries), because high blood flow in any remaining arteries increases the risk of hemorrhage secondary to volume overload.
Statistical analysis
The mean PCS, MCS and RCS and mean values of the specific component scores were calculated for the overall study population. Normally distributed baseline variables were summarized as the mean 6 SD, while numerical variables that did not show a normal distribution were summarized as the median and interquartile range.
To estimate the mean values of PCS, MCS and RCS, the score for our 15-item questionnaire, htTKV and dry weight at each time point, the least squares mean value [95% confidence interval (CI)] was calculated by using a linear mixed model. In this model, the hospital visit (time) was set as the fixed effect and repeated effect, while the patient identification number was the subject variable as the random effect. In addition, our covariance model used compound symmetry, assuming that patients are independent of each other and that the parameters for a particular patient have a fixed correlation that does not vary over time. Therefore, in the covariance matrix of the observations, within-patient covariance was set as the estimate of r p
Japan, Tokyo, Japan). All P-values were two-tailed and P-values <0.05 were considered statistically significant.
R E S U L T S
Among the 207 hemodialysis patients with ADPKD who underwent renal TAE from August 2010 to July 2014, 188 patients were enrolled in this study (Figure 1) , including 92 men and 96 women with a mean age of 56.7 6 9.1 years ( Table 2 ). All patients had severe flank pain for $3 days after renal TAE and epidural anesthesia was provided for pain relief, except in twelve patients who did not receive it because of thrombocytopenia. They received NSAIDs and/or pentazocine. High fever (>38 C) with marked elevation of inflammatory markers, such as serum C-reactive protein (CRP), continued for $1 week. All patients were treated with antibiotics, and NSAIDs were administered to control fever. Fever and elevation of CRP were normalized by 1 month after renal TAE. All patients eventually became anuric after slight macroscopic dark hematuria persisted for $6 months. The average hospital stay was 10 days after renal TAE for control of flank pain and/or fever and for adjustment of dry weight. Appropriate adjustment of dry weight was performed to avoid complications such as congestive heart failure, and no patient developed congestive heart failure while in the hospital. A pseudoaneurysm occurred at the femoral artery puncture site in one patient. Among six patients who dropped out of the study by 1 month, one patient died of unknown causes after discharge from the hospital and one patient underwent nephrectomy within 1 month because of severe renal cyst infection that was considered to be a complication of TAE (Supplementary Table S3 ). Among 11 patients who dropped out for unknown reasons, 7 were confirmed to be alive at 1 year after renal TAE, but the status of 4 patients could not be confirmed.
htTKV changed over time after renal TAE ( Figure 2 
and 49.67 (47.22-52.12; P <0.001), respectively (Table 3 and Figures 3-5) . The least squares mean value of the abdominal fullness score improved dramatically after renal TAE and there was also marked improvement in the least squares mean of the appetite score (Supplementary Appendix, Figure S1 ). Improvement of the heartburn score was noted as well. There was slight, but significant improvement of the scores for fever, bodily pain, cutting toenails and picking up objects from the floor, even though these scores were not low before TAE. On the other hand, scores for sleep and sleeping in the supine position were poor before renal TAE and the scores for these variables only improved slightly. The gross hematuria score temporarily became worse after renal TAE (because slight dark hematuria usually persists for $6 months following this procedure). However, among 15 patients with severe gross hematuria (a score of 1 or 2) before renal TAE, improvement of hematuria by at least 2 grades was noted in 10 patients after TAE. Also, among 15 patients who had severe bodily pain (a score of 1 or 2) before renal TAE, improvement of pain by at least 2 grades occurred in 11 patients after TAE. Scores for snoring, constipation and use of analgesics/sleeping medication/laxatives did not improve significantly after renal TAE. Table 4 shows that all of the SF-36 component scores and the scores for specific symptoms (except bodily pain, snoring and constipation) were significantly correlated with the sequential decrease of htTKV. The RCS showed the greatest improvement among the three SF-36 scores as htTKV decreased. Although there was considerable variation among the individual symptoms, abdominal fullness showed the greatest improvement. There was no significant association between the change in htTKV and changes in PCS, MCS and RCS (Supplementary Figure S2) . However, this comparison of the changes in QOL scores with the change in htTKV at 1 year after renal TAE was only performed in patients who did not drop out of the study before that time. Improvement of abdominal fullness, appetite, heartburn, bodily pain, fever and sleeping was significantly correlated with improvement of the SF-36 score, but changes of gross hematuria, snoring and constipation showed no significant correlation with the SF-36 score (Supplementary Table S4 ).
There was no significant association between baseline htTKV and/or htTLV and baseline PCS, MCS or RCS (Supplementary  Table S5 and Figure S6 ). When the baseline QOL score before renal TAE was compared between patients who dropped out and patients followed up for 1 year, there was no significant difference between the two groups (Supplementary Table S6 ), indicating that improvement of the average QOL score after renal TAE was not due to loss of certain patients from the study population.
D I S C U S S I O N
In the present study, we found considerable variation in the effect of renal TAE on the symptoms of ADPKD patients with massive kidneys. Abdominal fullness, appetite and heartburn all showed marked improvement after renal TAE. Improvement of appetite could have led to improved nutrition and dry weight (Supplementary Appendix, Figure S4 ), which might also have resulted in MCS and RCS reaching values close to average for the general Japanese population. There was significant improvement of PCS, MCS and RCS at 1 year after renal TAE, with a change of 3-6 points being noted. Since 10 points corresponds to 1 SD for the general Japanese population, it is considered that these improvements were clinically relevant. However, the PCS score was still low at 1 year after renal TAE. Snoring and constipation did not improve after renal TAE. Because restriction of water intake is required after renal TAE since patients become anuric, constipation is common following this procedure, while snoring might have been influenced by other factors.
After renal TAE, there was only slight improvement of the scores for fever, bodily pain, sleeping, sleeping in the supine position, cutting toenails and picking up objects from the floor. This suggested that some of these factors might not be closely correlated with htTKV, in agreement with our previous report [5] . Sleep disturbance could have been associated with renal dysfunction, because all of the patients were on dialysis [25] , but further research using polysomnography would be needed 2  8  1  1  8  0  2  4  3  5  2  2  6  0  3  V  K  T  t  H  n  a  e  M   9  1  8  1  9  9  9  1  6  6  2  2  0  1  7  2  7  3  2  3  I  C  %  5  9   7  6  4  1  6  4  6  1  7  9  8  1  8  5  3  2  8  8  8  2 FIGURE 2: Least squares mean (95% CI) of htTKV at each time point calculated by using a linear mixed model. htTKV decreased after renal TAE. SE, standard error; PF_N, physical functioning score adjusted by general Japanese population; RP_N, role physical score adjusted by general Japanese population; BP_N, bodily pain score adjusted by general Japanese population; GH_N, general health score adjusted by general Japanese population; VT_N, vitality score adjusted by general Japanese population; SF_N, social functioning score adjusted by general Japanese population; RE_N, role emotional score adjusted by general Japanese population; MH_N, mental health score adjusted by general Japanese population.
Alternatively, a greater reduction of renal volume might be required to improve these factors. Physical exertion (PCS score) is associated with both muscle strength and balance, and a longer follow-up period may have been needed for more improvement of these factors. On the other hand, abdominal distension, appetite and the MCS:RCS ratio seemed to be more strongly influenced by a reduction of renal volume. Renal TAE significantly improved abdominal fullness, appetite and heartburn. Thus patients with these symptoms would be expected to benefit from renal TAE. The change in htTKV was significantly correlated with changes in PCS, RCS and MCS ( Table 4 ), indicating that the SF-36 score would be expected to show greater improvement in patients with a larger decrease of htTKV. Therefore, patients in whom a marked decrease of kidney volume is expected should also benefit from renal TAE. Our previous study revealed that a marked decrease of kidney volume after renal TAE is more likely to be achieved in patients who are younger, patients with a shorter dialysis duration and patients with hypertension [15] .
After renal TAE, most patients had severe flank pain and high fever, but these symptoms were normalized within 1 month. The use of analgesics and the scores for fever and bodily pain were not worse at 1 month after renal TAE compared with before TAE, so we considered that the effect of these symptoms on the QOL scores was small. Loss of residual renal function after renal TAE is potentially a serious issue, because it was reported that complete loss of glomerular filtration is associated with a higher mortality rate [26, 27] . Residual renal function is also important for regulating fluid volume and allowing patients to have greater fluid intake. Urine volume decreased in all patients after renal TAE and eventually they became anuric, so they had to regulate fluid intake more carefully after the procedure. It is possible that stricter regulation of fluid intake might have had a negative influence on QOL. Also, if the dry weight was not adjusted properly after renal TAE, an inappropriate dry weight might have led to congestive heart failure and edema, which could have affected the QOL scores.
There was no significant association between baseline htTKV and/or htTLV and baseline PCS, MCS or RCS (Supplementary Table S5 and Figure S3 ). One reason for the lack of an association might be that these QOL scores are subjective and multifactorial and thus cannot be explained by simply htTKV or htTKV þ htTLV. This result is consistent with the findings of our previous cross-sectional study, which revealed that TKV þ TLV was not significantly associated with any of the SF-36 scores by multiple regression analysis, although it was closely correlated with abdominal distention [5] . Another reason might be that the patients overestimated their QOL before renal TAE, because ADPKD is a slow progressive disease, with the result that patients do not notice the decline in QOL. After an acute event (renal TAE), patients might have realized that their prior QOL was worse than they had previously thought. In addition, the perceived improvement of QOL might have been influenced by a placebo effect related to receiving active treatment. Our finding in this study that the decrease of htTKV was significantly correlated with improvement in QOL scores is not inconsistent with baseline htTKV and/or htTLV Rizk et al. [28] and Miskulin et al. [6] both reported that the PCS and MCS did not differ significantly between nondialysis ADPKD patients and the general population, with these scores being better than in patients with end-stage renal disease. However, the mean sum of both kidney volumes of their patients was 1873.4 mL and 2396.0 mL, respectively [6, 28] , while the median TKV before renal TAE was a much larger 4497.0 mL in the present study. In addition, all of our patients were on dialysis. Thus our results suggest that MCS and RCS might remain high in Japanese ADPKD patients on dialysis, although the average SF-36 score for patients with end-stage renal disease in Japan is unknown. One possible reason for higher MCS and RCS scores in Japanese patients might be that the dialysis environment (including techniques and heath care coverage) is supportive in Japan and there are almost 20 000 patients who have been on hemodialysis for >20 years [29] . This background might have influenced our results as well. On the other hand, physical strength could be impaired in Japanese dialysis patients, which might be a reason that the PCS score was still low after renal TAE.
It has been reported that kidney transplantation is the optimum treatment for selected patients with ADPKD [30] , and transplantation combined with nephrectomy might improve the QOL of ADPKD patients [7, 8] . However, very few donor kidneys are available in Japan, and some patients cannot receive kidney transplantation in Western countries because the limited number of potential donors raises questions about recipient priorities. Renal TAE may be a promising option for improving QOL in patients who are unable to receive kidney transplantation.
The first limitation of this study is that it was based on questionnaire surveys and the data were subjective. Also, only Japanese patients were included, but there might be ethnic differences, and dialysis conditions in Japan might differ from those elsewhere in the world. In addition, patients with a large htTKV might have been more likely to be recommended for renal TAE than those with a small htTKV, which could have led to selection bias. Furthermore, there were missing patients at each time of assessment because some patients did not return their questionnaire sheets or did not answer some questions properly and some doctors did not hand out the questionnaires to their patients. Failure to collect questionnaires from all patients might also have caused selection bias. While the overall number of missing questionnaires was not small, we considered that the use of a linear mixed model for data analysis reduced the influence on our results. Moreover, measurement error may have occurred due to calculating renal volume by the equation for the volume of an ellipsoid or calculating hepatic volume as the sum of the hepatic areas in each CT slice. We also assumed that htTLV did not change significantly for 1 year after renal TAE, thus it was only determined before TAE in each patient. If htTLV changed significantly during follow-up after TAE in some patients, it might have influenced their QOL scores. Finally, our classification of ascites has not been validated and the symptom of snoring was self-reported, so the data might be inaccurate.
In conclusion, renal TAE was effective for improving abdominal distention, appetite, heartburn and the MCS and RCS scores in ADPKD patients on hemodialysis with massive kidneys. However, renal TAE was less effective for sleep disturbance, constipation and physical strength (PCS score), suggesting that other interventions might be needed to alleviate these problems.
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